Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
This cost-effective tool will be of immense benefit to other high burden countries as well.
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Surgical treatment of chronic pancreatitis is challenging in children and especially laparoscopic surgery has been rarely reported, worldwide
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
The curriculum has been curated for General Physicians working in Clinikk
Subscribe To Our Newsletter & Stay Updated
